耐多药结核病临床治疗不良反应分析

Observation of Adverse Reactions in Clinical Treatment of Multidrug-Resistant Tuberculosis

目的探究耐多药结核病临床治疗的不良反应发生情况。方法选取该院2018年3月-2019年3月收治的80例耐多药结核病患者,通过左氧氟沙星、阿米卡星等核心药物对患者实施有效治疗。在治疗过程中对患者出现的不良反应予以观察和记录。结果使耐多药结核病发生的原因主要包括医疗决策因素,经济因素,患者存在较差的依从性和抵抗力,不合理使用药物等,所占比率分别为6.25%、8.75%、13.75%、35.00%、36.25%。患者发生的主要不良反应有肝功能损害、关节疼痛、血尿酸高、皮肤红染及局部皮下硬结等。结论患者在治疗期间需要积极引导其对不良反应的发生进行有效应对,通过积极的督导和干预,促进患者治疗依从性有效提高,从而使患者的治疗效果得到全面保证。

Objective To investigate the adverse reactions of multidrug-resistant tuberculosis(MDR-TB) in clinical treatment. Methods80 patients with MDR-TB admitted to the hospital from March 2018 to March 2019 were selected and treated effectively with core drugs such as levofloxacin and amikacin. Adverse reactions were observed and recorded during the treatment. Results The causes of MDR-TB mainly included medical decision-making factors, economic factors, poor compliance and resistance of patients, unreason-able drug use and so on.The ratios are 6.25%, 8.75%, 13.75%, 35.00%, and 36.25%, respectively. The main adverse reactions were liver function damage, joint pain, high blood uric acid, skin red staining and local subcutaneous sclerosis. Conclusion During the treatment, patients need to actively guide their effective response to adverse reactions. Through active supervision and intervention,patients’ treatment compliance can be effectively improved, so that the treatment effect of patients can be fully guaranteed.